Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 2
2021 1
2022 4
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin® R formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study.
Plum-Mörschel L, Singh G, Murugesan SMN, Marwah A, Panda J, Loganathan S, Athalye SN. Plum-Mörschel L, et al. Among authors: athalye sn. Diabetes Obes Metab. 2022 Apr;24(4):713-721. doi: 10.1111/dom.14635. Epub 2022 Jan 28. Diabetes Obes Metab. 2022. PMID: 34981621 Free PMC article. Clinical Trial.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.
Plum-Mörschel L, Klein O, Singh G, Murugesan SMN, Marwah A, Sharma N, Panda J, Loganathan S, Lakshmi GC, Athalye SN. Plum-Mörschel L, et al. Among authors: athalye sn. Diabetes Obes Metab. 2022 Sep;24(9):1819-1828. doi: 10.1111/dom.14768. Epub 2022 Jun 6. Diabetes Obes Metab. 2022. PMID: 35589611 Free PMC article. Clinical Trial.
Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study.
Lebovitz HE, Fleming A, Cherrington AD, Joshi S, Athalye SN, Loganathan S, Vishweswaramurthy A, Panda J, Marwah A. Lebovitz HE, et al. Among authors: athalye sn. Expert Opin Pharmacother. 2022 Nov;23(16):1855-1863. doi: 10.1080/14656566.2022.2141569. Epub 2022 Nov 9. Expert Opin Pharmacother. 2022. PMID: 36352762 Clinical Trial.
REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT.
Kr R, Rathod C, Darnule R, Loganathan S, Deodhar S, A R, Marwah A, Chaudhari NM, Thakur BK, Vaidyanathan S, Athalye SN. Kr R, et al. Among authors: athalye sn. Expert Opin Biol Ther. 2023 May;23(5):443-454. doi: 10.1080/14712598.2023.2204186. Epub 2023 Apr 28. Expert Opin Biol Ther. 2023. PMID: 37073744
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.
Andersen G, Singh G, Murugesan SMN, Gogineni R, Sharma N, Panda J, Marwah A, Loganathan S, Athalye SN. Andersen G, et al. Among authors: athalye sn. Diabetes Obes Metab. 2023 Jun;25(6):1485-1494. doi: 10.1111/dom.14994. Epub 2023 Feb 14. Diabetes Obes Metab. 2023. PMID: 36708333 Clinical Trial.
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.
Kumar S, De Souza R, Nadkar M, Guleria R, Trikha A, Joshi SR, Loganathan S, Vaidyanathan S, Marwah A, Athalye SN. Kumar S, et al. Among authors: athalye sn. Expert Opin Biol Ther. 2021 May;21(5):675-686. doi: 10.1080/14712598.2021.1905794. Epub 2021 Apr 9. Expert Opin Biol Ther. 2021. PMID: 33835886 Free PMC article. Clinical Trial.
12 results